Neuropathological basis of nonmotor manifestations of Parkinson's disease

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1114-1119

  Adler, Charles H ^a   Beach, Thomas G ^b  

^a MAYO CLINIC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

nonmotor signs; Parkinson's disease; synuclein

Indexed keywords

ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DIFFUSE LEWY BODY DISEASE; DYSPHAGIA; HUMAN; HYPOSMIA; NEUROPATHOLOGY; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; URINARY FREQUENCY; URINARY URGENCY; AUTONOMIC NEUROPATHY; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITIVE DYSFUNCTION; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 84962755420     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26605     Document Type: Article

References (73)

1. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27(5):617-626.
2. Adler CH, Stern MB. Redefining Parkinson's Disease. Clinical Insights: Parkinson's Disease: Diagnosis, Motor Symptoms and Non-Motor Features. 2013:7-19. Doi: 10.2217/ebo.13.29.
3. Beach TG, White CL, Hamilton RL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008;116(3):277-288.
4. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117(6):613-634.
5. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psych 1988;51(6):745-752.
6. Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neurol Neurosurg Psych 2004;63(7):742-749.
7. Beach TG, Adler CH, Sue LI, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008;115(4):445-451.
8. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008;65(8):1074-1080.
9. Iacono D, Geraci-Erck M, Rabin ML, et al. Parkinson disease and incidental Lewy body disease: just a question of time? Neurol 2015;85:1670-1679.
10. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurol 2012;79:2307-2314.
11. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115(4):437-444.
12. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119(6):689-702.
13. Sumikura H, Takao M, Hatsuta H, et al. Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Commun 2015;3:57.
14. Ito S, Takao M, Hatsuta H, et al. Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Int J Clin Exp Pathol 2014;7:1714-1723.
15. Sengoku R, Saito Y, Ikemura M, et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neurol Neurosurg Psych 2008;67(11):1072-1083.
16. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010;25(5):642-646.
17. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006;21(12):2062-2067.
18. Driver-Dunckley E, Adler CH, Hentz JG, et al. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Park Rel Disord 2014;20(11):1260-1262.
19. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurol 1994;44(2):266-268.
20. McKinnon J, Evidente V, Driver-Dunckley E, et al. Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disorders. Int J Neurosci 2010;120:36-39.
21. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22(11):1581-1586.
22. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 2012;124(5):665-680.
23. Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol 2012;124(5):643-664.
24. Oinas M, Paetau A, Myllykangas L, Notkola IL, Kalimo H, Polvikoski T. Alpha-synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: a population-based Vantaa 85 + study. Acta Neuropathol 2010;119(6):715-722.
25. Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related α-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathol 2012;32:13-22.
26. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurol 1996;46(2):388-393.
27. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16(4):622-630.
28. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurol 2006;66(6):845-851.
29. Adler CH, Hentz JG, Shill HA, et al. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Park Rel Disord 2011;17(6):456-458.
30. Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurol 2015;84(11):1104-1113.
31. Mahlknecht P, Iranzo A, Hogl B, et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurol 2015;84(7):654-658.
32. Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015;77(5):830-839.
33. Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. Alpha-synuclein in the inner retina in Parkinson disease. Ann Neurol 2014;75(6):964-966.
34. Beach TG, Carew J, Serrano G, et al. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett 2014;571:34-38.
35. Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013;14(8):754-762.
36. Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in Parkinson's disease. Mov Disord 2015;30(10):1413-1417.
37. VanderHorst VG, Samardzic T, Saper CB, et al. Alpha-synuclein pathology accumulates in sacral spinal visceral sensory pathways. Ann Neurol 2015;78(1):142-149.
38. Silveira-Moriyama L, Holton JL, Kingsbury A, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 2009;453(2):77-80.
39. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010;5(9):e12728.
40. Pouclet H, Lebouvier T, Coron E, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 2012;45(1):305-309.
41. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988;76(3):217-221.
42. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29(8):1010-1018.
43. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neurol Neurosurg Psych 2002;61(5):413-426.
44. Mu L, Sobotka S, Chen J, et al. Altered pharyngeal muscles in Parkinson disease. J Neurol Neurosurg Psych 2012;71(6):520-530.
45. Mu L, Sobotka S, Chen J, et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neurol Neurosurg Psych 2013;72(2):119-129.
46. Mu L, Sobotka S, Chen J, et al. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neurol Neurosurg Psych 2013;72(7):614-623.
47. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?. A cohort study. Neurol 2007;68(23):2012-2018.
48. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005;109(6):583-588.
49. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neurol Neurosurg Psych 2007;66(5):354-362.
50. Adler CH, Caviness JN, Sabbagh MN, et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:829-830.
51. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurol 2000;54(10):1916-1921.
52. Jellinger KA. Pathological substrate of dementia in Parkinson's disease—its relation to DLB and DLBD. Park Rel Disord 2006;12(2):119-120.
53. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alz Dis Assoc Disord 2009;23(3):295-297.
54. Choi SA, Evidente VG, Caviness JN, et al. Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia? Acta Neuropatholog 2009;119:147-149.
55. Dugger BN, Davis K, Malek-Ahmadi M, et al. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurol 2015;15:146.
56. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58(5):773-776.
57. Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120(6):829-830; author reply 831.
58. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000;100(3):285-290.
59. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72(4):587-598.
60. Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135(Pt 10):3005-3014.
61. Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000;57:1145-1150.
62. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurol 2005;64(8):1404-1410.
63. Nelson PT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010;20(1):66-79.
64. Howlett DR, Whitfield D, Johnson M, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 2015;25(4):401-408.
65. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59(1):102-112.
66. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psych 2003;74(7):852-856.
67. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133(Pt 6):1755-1762.
68. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-844.
69. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 1998;95(6):576-582.
70. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115(4):409-415.
71. Bertrand E, Lewandowska E, Stepien T, Szpak GM, Pasennik E, Modzelewska J. Amyloid angiopathy in idiopathic Parkinson's disease. Immunohistochemical and ultrastructural study. Folia Neuropathol 2008;46(4):255-270.
72. Ghebremedhin E, Rosenberger A, Rub U, et al. Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with Lewy body diseases. J Neurol Neurosurg Psych 2010;69(5):442-448.
73. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211.